Vasa’s VS-041 shows positive Phase Ic results in HFpEF trial
The trial assessed the narrow-spectrum MMP inhibitor across two doses in patients receiving background guideline-directed medical therapy.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance